Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPJAYASUNDERA, K. ThiranABUZAITOUN, Rebhi O.POPOVA, LiliaABALEM, Maria FernandaANDREWS, Chris A.LACY, Gabrielle D.FRESCO, David M.MUSCH, David C.2024-04-052024-04-052023AMERICAN JOURNAL OF OPHTHALMOLOGY, v.248, p.116-126, 20230002-9394https://observatorio.fm.usp.br/handle/OPI/59208PURPOSE: To evaluate aspects of construct validity of the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-related Anxiety Ques-tionnaire (MVAQ). center dot METHODS: Subjects with a clinical diagnosis of an inherited retinal disease (IRD) were recruited prospec-tively and 3 tests were used to assess construct valid-ity: the ability to distinguish different IRD phenotypes; test a priori hypothesis of an association between vision-related anxiety and vision-related disabilities; and corre-late MRDQ and MVAQ with the National Eye Insti-tute Visual Functioning Questionnaire 25 (NEI VFQ-25) and the Impact of Vision Impairment (IVI). One-way analysis of variance (ANOVA) was used to com-pare different phenotypes for mean domain scores for MRDQ/MVAQ. Pearson correlations were performed be-tween; Cone-Function Anxiety and Central Vision con-trolling for better eye visual acuity, Rod-Function Anxi-ety and Scotopic Function controlling for visual field area (III4e and IV4e), and scores of MRDQ/MVAQ, NEI VFQ-25, and IVI. center dot RESULTS: The study sample consisted of 146 pa-tients evenly divided between males and females, and mean age was 50 years. The 1-way ANOVA test was significant for distinguishing IRD phenotypes in 6 do-mains of MRDQ/MVAQ. Cone-Function Anxiety corre-lated with Central Vision controlling for visual acuity, Rod-Function Anxiety correlated with Scotopic Func-tion controlling for visual field area, and all domains in MRDQ/MVAQ had significant correlations with NEI VFQ-25 and IVI composite scores. center dot CONCLUSION: MRDQ and MVAQ domenstrate aspects of construct-validity set forth by the US Food and Drug Administration. The study futher supports the use of both patient-reported outcome measures in IRD clinical trials and natural history studies. (Am J Ophthalmol 2023;248: 116-126. (c) 2022 Elsevier Inc. All rights re-served.)engrestrictedAccessmental-healthquestionnaireanxietyruminationbehaviorsstressworrylifearticleCopyright ELSEVIER SCIENCE INC10.1016/j.ajo.2022.11.021Ophthalmology1879-1891